Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest cognitive dysfunction Stories

2012-08-14 10:25:10

ANN ARBOR, Mich., Aug. 14, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, today reported financial results for the three and six months ended June 30, 2012 and summarized operational highlights. Operational Highlights Expanding Synthetic Biologic Programs Enhanced our relationship with Intrexon by entering into a second worldwide exclusive channel collaboration for the development and...

2012-08-13 10:24:58

GERMANTOWN, Maryland, August 13, 2012 /PRNewswire/ -- A study conducted by researchers from the University of L'Aquila in Italy and Mars, Incorporated provides compelling new evidence that the regular consumption of dietary cocoa flavanols may improve cognitive function in elderly subjects with early memory decline. Just published online in the journal Hypertension, this current study significantly advances understanding of the benefits of flavanols by specifically exploring the...

2012-05-15 10:24:49

ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, 2012 and summarized operational highlights. Operational Highlights Management Team - Strengthened Clinical Development and Regulatory Affairs Functions Recruited former Chief Medical Officer of Clinical Data, Inc.,...

Research Confirms Menopause Causes Memory Problems
2012-03-17 03:58:01

According to research published in the journal Menopause, the journal of the North American Menopause Society, women really do suffer memory problems when going through menopause. Millions of women going through menopause have complained about forgetfulness or described having "brain fog" in their late 40s and 50s. In a new study, researchers gave women various cognitive tests to validate their experiences and provide some clues to what is happening in the brain as menopause hit....

2012-03-02 01:18:42

MGH researchers find desflurane may be safer anesthetic option for patients with Alzheimer's disease The association of the inhaled anesthetic isoflurane with Alzheimer's-disease-like changes in mammalian brains may by caused by the drug's effects on mitochondria, the structures in which most cellular energy is produced. In a study that will appear in Annals of Neurology and has received early online release, Massachusetts General Hospital (MGH) researchers report that administration of...

2012-02-08 10:16:53

In low- and middle-income countries, mild cognitive impairment–an intermediate state between normal signs of cognitive aging, such as becoming increasingly forgetful, and dementia, which may or may not progress–is consistently associated with higher disability and with neuropsychiatric symptoms but not with most socio-demographic factors, according to a large study published in this week's PLoS Medicine. The established 10/66 Dementia Research Group interviewed approximately 15...

2012-01-19 05:30:00

ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the initiation of the Phase II clinical trial of Trimesta(TM)( )(oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis (MS). This clinical trial is intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients at University...

2011-11-14 08:00:00

ANN ARBOR, Mich., Nov. 14, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its third quarter 2011 financial results for the period ended September 30, 2011, as well as updates since the beginning of the third quarter. Updates since the beginning of the third quarter include: Drug Development Programs Relapsing-Remitting Multiple Sclerosis (MS) As of September 19, 2011, the...

2011-11-11 08:00:00

ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced that the Company's drug candidate, Trimesta(TM) (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this...

2010-10-20 00:00:00

Offered as a simultaneous webcast and telephone audioconference premiering Tuesday, November 9, 2010, from 12:00 p.m.-1:00 p.m. ET, the continuing education activity seeks to implement strategies to improve assessment and management of cognitive dysfunction in patients with multiple sclerosis. Rockville, MD (PRWEB) October 19, 2010 CME Outfitters, LLC, (CMEO) an award-winning accredited provider of multidisciplinary continuing education (CE), is pleased to announce an upcoming...